entertainment -WSS

entertainment

author：hotspot 2025-10-02 14:22:49 - browse：4

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Cassava Sciences’ Alzheimer’s clinical trials should be halted

explore

WSS

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Use doctors trained outside the U.S. to ease the physician shortage

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Health tech investors get more selective as pandemic boom fades

Undocumented workers face uncertainty as immigration law takes effect in Florida

STAT wants to know your pick for a great summer read or listen

Wikipedia

entertainment

knowledge

Cancer drug shortages should be causing more outrage

How Robert F. Kennedy Jr. distorted vaccine science

The cancer drug shortage isn’t new — and neither are the solutions

Skip the lead apron during X

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Results on Novartis prostate cancer therapy could expand its use

As demand for Covid shots wanes, Moderna seeks its next success

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Wildfire smoke exposes gaps in outdoor worker protections

The biotech scorecard for Q3: 15 stock

hotspot

Dexcom's push to bring CGM to type 2 diabetes patients

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

'Screen and refer' systems are hurting patients

UnitedHealth, Optum discontinue NaviHealth name

Smaller biotechs seek to piggyback on weight loss drug boom

Smaller biotechs seek to piggyback on weight loss drug boom

hotspot

focus

explore

knowledge